[Retracted] The Clinical Efficacy and Economic Benefits of Recombinant Human Thrombopoietin for the Treatment of Chemotherapy or Chemoradiotherapy-Induced Thrombocytopenia
Table 3
Comparison of indicators in the use of rhTPO for treatment of grade II, III, and IV thrombocytopenia [n, (%)].
Indicators
Use of recombinant human thrombopoietin (rhTPO)
χ2 value
P Value
Grade II (n = 100)
Grade III (n = 94)
Grade IV (n = 39)
Delay of the next chemoradiotherapy/radiotherapy cycle due to platelet decline
No
56 (56.0)
40 (42.6)
14 (35.9)
5.921
0.052
Yes
44 (44.0)
54 (57.4)
25 (64.1)
Regimen change due to altered platelet count
No
85 (85.0)
88 (93.6)
32 (82.1)
4.962
0.084
Yes
15 (15.0)
6 (6.4)
7 (17.9)
Dose reduction of chemoradiotherapy due to platelet decline
No
85 (85.0)
81 (86.2)
31 (79.5)
0.970
0.616
Yes
15 (15.0)
13 (13.8)
8 (20.5)
Days of treatment
5.00 (3.00, 6.00)
6.00 (4.00, 8.00)
6.00 (4.00, 11.00)
16.319
<0.001
Time to increase platelets (days)
3.00 (2.00, 5.00)
5.50 (3.00, 8.00)
6.00 (3.00, 11.00)
31.828
<0.001
Delay of the next chemoradiotherapy cycle (days)
0 (0, 5.75)>
3.00 (0, 9.25)
3.00 (0, 8.00)
8.460
0.015
Prolonged hospitalization due to platelet decline (days)
1.00 (0, 6.00)
3.50 (0, 7.00)
5.00 (0, 8.00)
7.908
0.019
Increased hospitalization costs due to platelet decline
